CompanyROIVNasdaqLondon

Roivant Sciences Ltd.

Roivant is a commercial-stage biopharmaceutical company developing small molecule and monoclonal antibody therapies.

SEC EDGAR ClinicalTrials.gov phrontierstudy.com

DEF 14ASep 28Latest SEC filing

Sep 8Latest story

September 2026

Roivant details Phase 2 PHocus data for mosliciguat, unveils ongoing Phase 3 PHrontier trial

Sep 8Clinical readoutRoivant Sciences Ltd.

August 2026

FDA approves Roivant's LISRAYA for dermatomyositis, launch begins immediately

Aug 28Regulatory decisionbrepocitinib Roivant Sciences Ltd.

Roivant reports Q1 fiscal 2027 results, pipeline on track across four vants

Aug 6Quarterly updateRoivant Sciences Ltd.